Business
Oncolytics Biotech(R) Announces Voting Results from the Annual General Meeting of Shareholders
CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / May 3, 2019 / Oncolytics Biotech ® Inc....
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"Oncolytics Biotech(R) Announces Voting Results from the Annual General Meeting of ShareholdersCALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / May 3, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the voting results from its Annual General Meeting of Shareholders held on Thursday, May 2nd, 2019. A total of 46.21% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.On a vote by ballot, the following six nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows: Director For % Withheld % Deborah Brown 2,133,684 87.21 % 312,958 12.79 % Matt Coffey 2,177,071 88.98 % 269,571 11.02 % Angela Holtham 2,162,432 88.38 % 284,210 11.62 % Wayne Pisano 2,126,840 86.93 % 319,802 13.07 % William G. Rice 2,120,389 86.67 % 326,253 13.33 % Bernd R. Seizinger 2,161,321 88.34 % 285,321 11.66 % In addition to the election of all nominees listed as directors in the management information circular, dated March 7, 2019, Oncolytics shareholders approved all other resolutions placed before the meeting. These included fixing the number of directors of the Corporation for the ensuing year at six and appointing auditors for the Corporation for the ensuing year.Mark Lievonen, at the request of the board and senior management, has served beyond the mandated term limit of 12 years and did not stand for re-election. Mr. Lievonen will continue as a consultant to Oncolytics Biotech’s senior management team and the Board of Directors.For more details on the matters covered at the annual meeting please refer to the Corporation's management information circular available on SEDAR at www.sedar.com. Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.About Oncolytics Biotech Inc. Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype - turning \"cold\" tumors \"hot\" - throug...